Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.
about
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart diseaseOrigin and therapy for hypertriglyceridaemia in type 2 diabetesDipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protectionGLP-1 and cardioprotection: from bench to bedsideThe Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic ReviewSitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoformsImpact of glycemic control on healthcare resource utilization and costs of type 2 diabetes: current and future pharmacologic approaches to improving outcomes.The stem cell adjuvant with Exendin-4 repairs the heart after myocardial infarction via STAT3 activation.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemDPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction.Optimal candidates for the switch from glimepiride to sitagliptin to reduce hypoglycemia in patients with type 2 diabetes mellitus.Effects of Exendin-4 on bone marrow mesenchymal stem cell proliferation, migration and apoptosis in vitro.A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes.Effect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients.Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular eventsThe effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus.Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese ratsRationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study).Genetic variants in PCSK1 gene are associated with the risk of coronary artery disease in type 2 diabetes in a Chinese Han population: a case control study.Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.Is glucose control important for prevention of cardiovascular disease in diabetes?Cardiac autonomic neuropathy in patients with diabetes mellitus.Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathwayA review of gliptins in 2011.Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.Cardiovascular autonomic neuropathies as complications of diabetes mellitus.Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.Adipose tissue, hormones, and treatment of type 1 diabetes.Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease.Principles of endocrinology.Cardiovascular effects of gliptins.Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus--targeting thrombogenesis.The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.The cardiovascular safety of incretin-based therapies: a review of the evidence.
P2860
Q26777994-2213E0DB-A184-4925-A715-1F0A6A62ACC2Q26784211-C62B7DB2-55E3-4B54-A7D6-B9B5C025C9D2Q26824004-BA5E88FD-CD0E-41AE-8619-91519C6C21A8Q27011819-DD069FDD-027B-42DE-984E-953080764322Q27024984-A6725204-F59B-4A05-9E76-C41EDEE7D066Q28078225-9B26BA4F-A4BF-4598-B976-FC84679B499AQ28535415-716E6740-6326-41B6-8A0B-BB6DCCD23E8DQ33652884-03B60532-5175-401D-B289-64F3F08513E8Q34011497-238521D7-01FA-43BD-AC2B-E90CFF012A91Q34062829-A4164550-B905-4CE9-AAA8-F833C93364D6Q34109066-CCE2B02C-062C-4F74-9B21-69C5E992FBB7Q34785887-31993521-0351-41A5-B335-66D7918555D8Q35260937-644A13D5-BAF4-48B5-B6E1-FEA096D0C52AQ35926017-A322129C-1938-4A49-A74D-B65834702272Q36428082-658B9E66-F3DA-41EE-BA21-4A6B7C03C48BQ36448319-276CCB47-B3AA-4299-9ECE-60E4D444F7BEQ36611527-25B7F5BD-4E68-43DF-A9B3-2006FAB207F2Q36845055-DD467752-7952-4E0D-9C5B-98B85DCAA239Q36946065-9729EBCA-EB67-4821-82F4-840C0824C27FQ37113253-76624651-0F2A-4CF8-AC4C-F51458E4C295Q37525540-3AFC7237-192F-4E36-8D72-B8937037A852Q37562586-7A5790FA-0490-4B7B-BFEC-B15BD136A0BFQ37577137-BF153CAD-6E4E-4749-826E-503E3FD04061Q37598878-400596E6-CCC0-4F3A-8061-B7A59437D866Q37618348-AB1C35F7-0E4D-4F79-B69C-0EADAB4C0BF7Q37965612-A14E608F-E034-4AD3-AA06-312D57F1E33FQ37965613-050D2D20-A16E-4DFF-B9EF-62AA80441DB4Q37982112-DA9D810B-7FF8-4E67-9088-F6D1F4908138Q37988796-AB5C3D92-EF73-494C-ACE8-D9714659627EQ38010243-596A59AF-FC7B-47F9-9F9B-C4AD1428C1C6Q38012068-6038D8B7-B63C-430A-903E-42DEC3B3A925Q38027744-F4CEF160-85D6-4147-BAF1-8AEEAD53FA06Q38042110-A3A851EB-179F-4687-A367-E1CCB4A4A606Q38067472-76E2DDBF-B66E-40B6-87B5-942BC9C6D80FQ38072259-E47051A8-0BD2-4E0D-9FD2-C1DA78E7EA15Q38077284-6E25151F-1C9D-4D3F-B12C-F1D013404B46Q38104293-1F8CA1A5-B4B6-443F-9D36-414498FA911EQ38113092-F2E29DA5-5547-4453-9AD8-CBE13F0BCE57Q38113093-2759E4EB-02D1-40FA-B72B-8D1E57583105Q38134902-CF0635BC-1C4D-4F16-9776-4871B0C8E438
P2860
Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Glucagon-like peptide-1-based ...... king beyond glycaemic control.
@en
Glucagon-like peptide-1-based ...... king beyond glycaemic control.
@nl
type
label
Glucagon-like peptide-1-based ...... king beyond glycaemic control.
@en
Glucagon-like peptide-1-based ...... king beyond glycaemic control.
@nl
prefLabel
Glucagon-like peptide-1-based ...... king beyond glycaemic control.
@en
Glucagon-like peptide-1-based ...... king beyond glycaemic control.
@nl
P2093
P2860
P1476
Glucagon-like peptide-1-based ...... oking beyond glycaemic control
@en
P2093
A Karagiannis
A Panagiotou
D P Mikhailidis
F Adamidou
P Anagnostis
P2860
P304
P356
10.1111/J.1463-1326.2010.01345.X
P577
2011-04-01T00:00:00Z